Markers of Atrial Cardiopathay

November 28, 2022 updated by: Mariam Zarief Farhan, Assiut University
Marker of atrial cardiopathay as apredictor value of ischemic stroke

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

detection of the presence of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with a one-year follow-up for any cardioembolic events (stroke /TIA).

Study Type

Observational

Enrollment (Anticipated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
      • Assiut, Egypt, 23123
        • Recruiting
        • Mariam zarief farhan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 90 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

- Patients complaining of palpitation referred for Holter monitoring

Description

Inclusion Criteria:

  • Patients complaining of palpitation referred for Holter monitoring

Exclusion Criteria:

  • • Valvular AF, moderate to severe mitral/ tricuspid/ aortic stenosis or regurgitation.

    • Recent myocardial infarction within 3 months.
    • Acute pulmonary embolism.
    • Newly onset AF during or shortly after cardiac surgery.
    • Specific type of cardiomyopathy such as cardiac amyloidosis, obstructive hypertrophic cardiomyopathy.

Decompensation stage of organ failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of any underlying arrythmia after holter monitoring for twenty four hours
Time Frame: Detection of any underlying arrythmia after holter monitoring for twenty four hours
Detection of any underlying arrythmia after holter monitoring for twenty four hours
Detection of any underlying arrythmia after holter monitoring for twenty four hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA).
Time Frame: Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA).
Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA).
Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Principal Investigator: Mohammed Aboelkassem Farghal, professor, Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 30, 2022

Primary Completion (Anticipated)

November 1, 2025

Study Completion (Anticipated)

November 1, 2025

Study Registration Dates

First Submitted

November 2, 2022

First Submitted That Met QC Criteria

November 13, 2022

First Posted (Actual)

November 21, 2022

Study Record Updates

Last Update Posted (Actual)

November 30, 2022

Last Update Submitted That Met QC Criteria

November 28, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • atrial cardiopathay

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Cardiopathy

Clinical Trials on Holter ,Echo , Speckle tracking echocardiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe